Lortab®
Hydrocodone and Acetaminophen · oral tablet
Analgesics
Approved uses
Pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
5 mg/325 mg: 1 to 2 tablets every 4 to 6 hours as needed, not to exceed 8 tablets a day. 7.5 mg/325 mg or 10 mg/325 mg: 1 tablet every 4 to 6 hours as needed, not to exceed 6 tablets a day. Start at the lowest dose that gives adequate analgesia and titrate to response.
Schedule II; the acetaminophen ceiling of 4,000 mg a day still applies across all products
Contraindications
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity to hydrocodone or acetaminophen, such as anaphylaxis
Tablets 5 mg/325 mg, 7.5 mg/325 mg, 10 mg/325 mg; bottles of 100 (all), 500 (5 and 10 mg) and 1000 (10 mg); unit dose packages of 100
Hydrocodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. Its principal therapeutic action is analgesia, and it produces respiratory depression by direct action on brain stem respiratory centers. Acetaminophen is a non-opiate, non-salicylate analgesic and antipyretic. The precise mechanism of its analgesic properties is not established but is thought to involve central actions. A narrative review states that acetaminophen is relatively selective for COX-2 but less potent to inhibit COX than NSAIDs, and that it is very likely to be a prodrug converted to the metabolite AM404, which is speculated to inhibit COX-2 to prevent the biosynthesis of prostaglandins responsible for nociception.
Warnings & Precautions
- Addiction, abuse and misuse: addiction can occur at recommended doses, and the risks of addiction, abuse, misuse, overdose and death can occur at any dosage or duration. Assess each patient's risk before prescribing and reassess all patients regularly for the development of these behaviors and conditions.
- Respiratory depression: serious, life-threatening or fatal respiratory depression may occur, especially during initiation or following a dosage increase. Opioids can also cause sleep-related breathing disorders, including central sleep apnea and sleep-related hypoxemia; in patients who present with central sleep apnea, consider decreasing the opioid dosage using best practices for opioid taper.
- Accidental ingestion: even one dose, especially by children, can result in a fatal overdose.
- Opioid overdose: inform patients and caregivers about opioid overdose reversal agents, such as naloxone or nalmefene, and discuss access to one, especially if the patient has risk factors for overdose or if household members, including children, or other close contacts are at risk for accidental ingestion or opioid overdose.
- Profound sedation, respiratory depression, coma and death: these may result from use with benzodiazepines or other CNS depressants, including alcohol. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate, and prescribe the lowest effective dosages and minimum durations of concomitant use.
- Neonatal opioid withdrawal syndrome: use for an extended period during pregnancy can cause withdrawal in the neonate, which may be life-threatening if not recognized and treated. Advise pregnant women using opioids for an extended period of the risk, and ensure that appropriate treatment will be available.
- Opioid Analgesic REMS: the FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for these products. Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription.
- Increased hydrocodone plasma concentrations: CYP3A4 inhibitors, such as erythromycin, ketoconazole or ritonavir, or stopping a CYP3A4 inducer, such as rifampin, carbamazepine or phenytoin, may increase hydrocodone plasma concentrations and may cause potentially fatal respiratory depression; monitor for respiratory depression and sedation, evaluate at frequent intervals, and consider a dose reduction until drug effects are stable.
- Opioid withdrawal and loss of analgesia: adding a CYP3A4 inducer, or stopping a CYP3A4 inhibitor such as a macrolide antibiotic, could lower hydrocodone plasma concentrations, decrease opioid efficacy or possibly lead to a withdrawal syndrome in a patient who has developed physical dependence. Follow patients at frequent intervals and consider a higher opioid dose if needed to keep adequate analgesia or if withdrawal symptoms occur.
- Hepatotoxicity: acetaminophen has been associated with acute liver failure, at times resulting in liver transplant and death, mostly at doses that exceed 4,000 milligrams per day and often with more than one acetaminophen-containing product. The risk is higher with underlying liver disease and in those who ingest alcohol while taking acetaminophen. Instruct patients not to use more than one acetaminophen-containing product and to seek medical attention immediately if they take more than 4,000 milligrams per day.
- Opioid-induced hyperalgesia: an opioid analgesic may paradoxically cause an increase in pain or in sensitivity to pain, which differs from tolerance. If it is suspected, carefully consider decreasing the dose of the current opioid analgesic or opioid rotation.
- Respiratory depression in chronic pulmonary disease: patients with significant chronic obstructive pulmonary disease or cor pulmonale, a substantially decreased respiratory reserve, hypoxia, hypercapnia or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages. Regularly evaluate these patients, particularly when initiating and titrating the drug, or consider non-opioid analgesics.
- Respiratory depression in elderly or debilitated patients: life-threatening respiratory depression is more likely in elderly, cachectic or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients. Regularly evaluate these patients, particularly when initiating and titrating the drug and when it is given with other drugs that depress respiration, or consider non-opioid analgesics.
- Adrenal insufficiency: cases have been reported with opioid use, more often after more than one month of use. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If it is diagnosed, treat with physiologic replacement doses of corticosteroids, wean the patient off the opioid, and continue corticosteroid treatment until adrenal function recovers.
- Severe hypotension: the drug may cause severe hypotension, including orthostatic hypotension and syncope in ambulatory patients. The risk is higher with reduced blood volume or with certain CNS depressants, such as phenothiazines or general anesthetics. Regularly evaluate patients for signs of hypotension after initiating or titrating the dosage. Avoid use in circulatory shock, because the drug may cause vasodilatation that further reduces cardiac output and blood pressure.
- Serious skin reactions: rarely, acetaminophen may cause acute generalized exanthematous pustulosis, Stevens-Johnson syndrome and toxic epidermal necrolysis, which can be fatal; stop the drug at the first sign of skin rash or any other sign of hypersensitivity.
- Hypersensitivity and anaphylaxis: hypersensitivity and anaphylaxis have been reported after marketing with acetaminophen, with infrequent reports of life-threatening anaphylaxis needing emergency care. Instruct patients to stop the drug immediately and seek medical care if they have these symptoms. Do not prescribe it for patients with acetaminophen allergy.
- Increased intracranial pressure: in patients who may be susceptible to the intracranial effects of carbon dioxide retention, such as those with increased intracranial pressure or brain tumors, the drug may reduce respiratory drive, and the resulting retention can further increase intracranial pressure. Watch these patients for sedation and respiratory depression, particularly when starting therapy. Opioids may also obscure the clinical course after a head injury; avoid use in impaired consciousness or coma.
- Gastrointestinal complications: opioids may obscure the diagnosis or clinical course in patients with acute abdominal conditions. Hydrocodone may cause spasm of the sphincter of Oddi, and opioids may cause increases in serum amylase; regularly evaluate patients with biliary tract disease, including acute pancreatitis, for worsening symptoms. The risk of opioid-induced esophageal dysfunction may increase with opioid dose and duration; regularly evaluate patients for its signs and symptoms.
- Seizures: hydrocodone may increase the frequency of seizures in patients with seizure disorders and may increase the risk of seizures in other settings associated with them. Regularly evaluate patients with a history of seizure disorders for worsened seizure control.
- Withdrawal syndrome: do not rapidly reduce or abruptly stop the drug in a patient physically dependent on opioids, because rapid tapering may lead to a withdrawal syndrome and return of pain. When stopping the drug in a physically dependent patient, gradually taper the dosage. Mixed agonist/antagonist and partial agonist analgesics, such as pentazocine, nalbuphine, butorphanol or buprenorphine, may reduce the analgesic effect or precipitate withdrawal, so avoid them.
- Serotonin syndrome: use with other drugs that affect the serotonergic neurotransmitter system, such as SSRIs, SNRIs, tricyclic antidepressants, triptans or MAOIs, including linezolid and intravenous methylene blue, has resulted in serotonin syndrome; stop the drug immediately if it is suspected. Use is not recommended in patients taking MAOIs or within 14 days of stopping such treatment.
- Impaired mental or physical abilities: the drug may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to its effects and know how they will react.
- Increased degree of respiratory depression: hydrocodone may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. Decrease the dosage of the drug and/or the muscle relaxant, such as cyclobenzaprine or metaxalone, as necessary, and consider recommending or prescribing an opioid overdose reversal agent.
- Urinary retention and severe constipation: use with anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Evaluate patients for signs and symptoms of urinary retention or reduced gastric motility.
- Higher plasma hydrocodone concentrations: patients with hepatic or renal impairment may have higher plasma hydrocodone concentrations than those with normal function. Use a low initial dose and follow closely for adverse events such as respiratory depression and sedation. In severe hepatic or renal disease, follow the effects of therapy with serial liver and/or renal function tests.
- False-positive urinary 5-hydroxyindoleacetic acid results: acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.
Common Side Effects
The most frequently reported adverse reactions are light-headedness, dizziness, sedation, nausea and vomiting. Constipation, drowsiness and mental clouding are also reported.
Pregnancy: There are no adequate and well-controlled studies in pregnant women; use only if the potential benefit justifies the potential risk to the fetus. Use for an extended period during pregnancy can cause neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. Not recommended during or immediately prior to labor.
Lactation: Hydrocodone is present in human milk. Monitor infants exposed through breast milk for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breastfeeding is stopped.
Safety and effectiveness in pediatric patients have not been established.